Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246651 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP2C19PIK3CD | |
| SCHEMBL7846935 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C19PIK3CD | |
| SCHEMBL7837815 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C19PIK3CD | |
| SCHEMBL607460 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C19PIK3CD | |
| SCHEMBL28312356 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C19PIK3CD | |
| SCHEMBL12168243 | 0.76 | TSHR (0.40) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL29190394 | 0.74 | TSHR (0.38) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL18838590 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL1576713 | 0.69 | — | — | |
| SCHEMBL1085851 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | ALDH1A1 354/4885TSHR 3376/4885CYP2C19 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.